Clinicians frequently have to decide when dialysis should be initiated and which modality should be used to support kidney function in critically ill patients with acute kidney injury. In most instances, these decisions are made based on the consideration of a variety of factors including patient condition, available resources and prevailing local practice experience. There is a wide variation worldwide in how these factors influence the timing of initiation and the utilization of various modalities. In this article, we review the therapeutic goals of renal support and the relative advantages and shortcomings of different dialysis techniques. We describe strategies for matching the timing of initiation to the choice of modality to individualize renal support in intensive care unit patients.

Keywords:
Dialysis, Renal replacement therapy, Timing of initiation, Outcomes, Fluid balance
1.
Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008;359:7–20.
2.
Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, Lo S, McArthur C, McGuinness S, Myburgh J, Norton R, Scheinkestel C, Su S: Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 2009;361:1627–1638.
3.
Mehta RL: Indications for dialysis in the ICU: renal replacement vs renal support. Blood Purif 2001;19:227–232.
4.
KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012;289–115.
5.
Ostermann M, Chang RW: Correlation between parameters at initiation of renal replacement therapy and outcome in patients with acute kidney injury. Crit Care 2009;13:R175.
6.
Chou YH, Huang TM, Wu VC, Wang CY, Shiao CC, Lai CF, Tsai HB, Chao CT, Young GH, Wang WJ, Kao TW, Lin SL, Han YY, Chou A, Lin TH, Yang YW, Chen YM, Tsai PR, Lin YF, Huang JW, Chiang WC, Chou NK, Ko WJ, Wu KD, Tsai TJ, Group NS: Impact of timing of renal replacement therapy initiation on outcome of septic acute kidney injury. Crit Care 2011;15:R134.
7.
Ostermann M, Dickie H, Barrett NA: Renal replacement therapy in critically ill patients with acute kidney injury – when to start. Nephrol Dial Transplant 2012;27:2242–2248.
8.
Heyman SN, Rosenberger C, Rosen S: Acute kidney injury: lessons from experimental models. Contrib Nephrol 2011;169:286–296.
9.
Venkataraman R, Palevsky P, Kellum JA: Adequacy of dialysis in acute renal failure. Semin Nephrol 2005;25:120–124.
10.
Bagshaw SM, Brindley PG, Gibney N, Bellomo R: Best evidence in critical care medicine. Continuous or intermittent renal replacement for treatment of severe acute kidney injury in critically ill patients. Can J Anaesth 2007;54:845–847.
11.
Prowle JR, Ishikawa K, May CN, Bellomo R: Renal blood flow during acute renal failure in man. Blood Purif 2009;28:216–225.
12.
Rabindranath K, Adams J, Macleod AM, Muirhead N: Intermittent versus continuous renal replacement therapy for acute renal failure in adults. Cochrane Database Syst Rev 2007:CD003773.
13.
Bagshaw SM, Brophy PD, Cruz D, Ronco C: Fluid balance as a biomarker: impact of fluid overload on outcome in critically ill patients with acute kidney injury. Crit Care 2008;12:169.
14.
Paganini EP, Sandy D, Moreno L, Kozlowski L, Sakai K: The effect of sodium and ultrafiltration modelling on plasma volume changes and haemodynamic stability in intensive care patients receiving haemodialysis for acute renal failure: a prospective, stratified, randomized, cross-over study. Nephrol Dial Transplant 1996;11(suppl 8):32–37.
15.
Schortgen F, Soubrier N, Delclaux C, Thuong M, Girou E, Brun-Buisson C, Lemaire F, Brochard L: Hemodynamic tolerance of intermittent hemodialysis in critically ill patients: usefulness of practice guidelines. Am J Respir Crit Care Med 2000;162:197–202.
16.
Ronco C, Bellomo R, Brendolan A, Pinna V, La Greca G: Brain density changes during renal replacement in critically ill patients with acute renal failure. Continuous hemofiltration versus intermittent hemodialysis. J Nephrol 1999;12:173–178.
17.
Fieghen HE, Friedrich JO, Burns KE, Nisenbaum R, Adhikari NK, Hladunewich MA, Lapinsky SE, Richardson RM, Wald R, Group UoTAKIR: The hemodynamic tolerability and feasibility of sustained low efficiency dialysis in the management of critically ill patients with acute kidney injury. BMC Nephrol 2010;11:32.
18.
Palevsky PM, Zhang JH, O’Connor TZ, Chertow GM, Crowley ST, Choudhury D, Finkel K, Kellum JA, Paganini E, Schein RM, Smith MW, Swanson KM, Thompson BT, Vijayan A, Watnick S, Star RA, Peduzzi P: Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008;359:7–20.
19.
Ponce D, Brito GA, Abrão JG, Balb AL: Different prescribed doses of high-volume peritoneal dialysis and outcome of patients with acute kidney injury. Adv Perit Dial 2011;27:118–124.
20.
Ponce D, Berbel MN, Regina de Goes C, Almeida CT, Balbi AL: High-volume peritoneal dialysis in acute kidney injury: indications and limitations. Clin J Am Soc Nephrol 2012;7:887–894.
21.
Brochard L, Abroug F, Brenner M, Broccard AF, Danner RL, Ferrer M, Laghi F, Magder S, Papazian L, Pelosi P, Polderman KH: An Official ATS/ERS/ESICM/SCCM/SRLF Statement: Prevention and Management of Acute Renal Failure in the ICU Patient: an international consensus conference in intensive care medicine. Am J Respir Crit Care Med 2010;181:1128–1155.
22.
Marshall MR, Golper TA, Shaver MJ, Alam MG, Chatoth DK: Urea kinetics during sustained low-efficiency dialysis in critically ill patients requiring renal replacement therapy. Am J Kidney Dis 2002;39:556–570.
23.
Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, La Greca G: Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000;356:26–30.
24.
Schiffl H, Lang SM, Fischer R: Daily hemodialysis and the outcome of acute renal failure. N Engl J Med 2002;346:305–310.
25.
Tolwani AJ, Campbell RC, Stofan BS, Lai KR, Oster RA, Wille KM: Standard versus high-dose CVVHDF for ICU-related acute renal failure. J Am Soc Nephrol 2008;19:1233–1238.
26.
Vesconi S, Cruz DN, Fumagalli R, Kindgen-Milles D, Monti G, Marinho A, Mariano F, Formica M, Marchesi M, Rene R, Livigni S, Ronco C: Delivered dose of renal replacement therapy and mortality in critically ill patients with acute kidney injury. Crit Care 2009;13:R57.
27.
Claure-Del Granado R, Macedo E, Chertow GM, Soroko S, Himmelfarb J, Ikizler TA, Paganini EP, Mehta RL: Toward the optimal dose metric in continuous renal replacement therapy. Int J Artif Organs, E-pub ahead of print.
28.
Goldstein SL, Somers MJ, Baum MA, Symons JM, Brophy PD, Blowey D, Bunchman TE, Baker C, Mottes T, McAfee N, Barnett J, Morrison G, Rogers K, Fortenberry JD: Pediatric patients with multi-organ dysfunction syndrome receiving continuous renal replacement therapy. Kidney Int 2005;67:653–658.
29.
Payen D, de Pont A, Sakr Y, Spies C, Reinhart K, Vincent J, Investigators SOiAIPS: A positive fluid balance is associated with a worse outcome in patients with acute renal failure. Crit Care 2008;12:R74.
30.
Foland JA, Fortenberry JD, Warshaw BL, Pettignano R, Merritt RK, Heard ML, Rogers K, Reid C, Tanner AJ, Easley KA: Fluid overload before continuous hemofiltration and survival in critically ill children: a retrospective analysis. Crit Care Med 2004;32:1771–1776.
31.
Brandstrup B, Engquist A: Is postoperative mortality affected by liberal intravenous fluid therapy? Presentation of a Cochrane analysis and a literature review. Ugeskr Laeger 2003;165:1342–1345.
32.
Brandstrup B, Tønnesen H, Beier-Holgersen R, Hjortsø E, Ørding H, Lindorff-Larsen K, Rasmussen MS, Lanng C, Wallin L, Iversen LH, Gramkow CS, Okholm M, Blemmer T, Svendsen PE, Rottensten HH, Thage B, Riis J, Jeppesen IS, Teilum D, Christensen AM, Graungaard B, Pott F: Effects of intravenous fluid restriction on postoperative complications: comparison of two perioperative fluid regimens: a randomized assessor-blinded multicenter trial. Ann Surg 2003;238:641–648.
33.
Bouchard J, Soroko SB, Chertow GM, Himmelfarb J, Ikizler TA, Paganini EP, Mehta RL: Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int 2009;76:422–427.
34.
Alsous F, Khamiees M, DeGirolamo A, Amoateng-Adjepong Y, Manthous CA: Negative fluid balance predicts survival in patients with septic shock: a retrospective pilot study. Chest 2000;117:1749–1754.
35.
Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D, Investigators SOiAIP: Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006;34:344–353.
36.
Bouchard J, Mehta RL: Fluid accumulation and acute kidney injury: consequence or cause. Curr Opin Crit Care 2009;15:509–513.
37.
Cantarovich F, Rangoonwala B, Lorenz H, Verho M, Esnault VL, Group H-DFiARFS: High-dose furosemide for established ARF: a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Am J Kidney Dis 2004;44:402–409.
38.
Mahesh B, Yim B, Robson D, Pillai R, Ratnatunga C, Pigott D: Does furosemide prevent renal dysfunction in high-risk cardiac surgical patients? Results of a double-blinded prospective randomised trial. Eur J Cardiothorac Surg 2008;33:370–376.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.